Chronic Idiopathic Constipation (CIC) discusses conventional therapies: bulking agents, softeners, stimulants, osmotics; recent additions and investigational agents: prucalopride, plecanatide, linaclotide, lubiprostone; non-pharmacologic therapies and their place relative to pharmacotherapy: dietary, mechanical, behavioral, and surgical interventions; biofeedback; and clinical pearls and difficult-to-treat cases.

After reviewing Chronic Idiopathic Constipation (CIC), you will be able to:
• Describe the pathophysiology of chronic idiopathic constipation
• Describe the benefits and risks of pharmacotherapy for chronic idiopathic constipation and take them into account when formulating a treatment plan for different patients
• Formulate an evidence-based treatment plan for a variety of patients with chronic idiopathic constipation.
• Recommend therapy changes in patients with chronic idiopathic constipation who do not respond to a previously prescribed treatment

Target Audience:
Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with chronic idiopathic constipation.

After viewing Updates in Migraine Headaches, you will be able to:
• Describe the prevalence of migraine symptoms and the impact that these symptoms have on efficacy of anti-migraine therapy and functional status
• Describe the sometimes variable manifestations (e.g., incidence and clinical presentation) of migraine headaches, depending on age and sex
• Recall emerging therapies for the treatment and prevention of chronic migraine headache and anticipate their place in therapy
• Support team-based learning and communication between all clinicians involved with the care of patients suffering with migraines
• Given a series of patient cases, diagnosis and treat migraine headaches by employing current treatment guidelines, using evidence-based therapy algorithms, and providing individualized approaches to care

Target Audiences:
Healthcare professionals who are: primary care physicians, neurologists, headache specialists, nurse practitioners, physician assistants, nurses, OB-GYN specialists, pharmacists, and those who otherwise commonly care for or clinically encounter patients who may experience migraine headache.

After completing Adult Growth Hormone Deficiency (GHD), you will be able to:
• Summarize present guidelines for the diagnosis of GHD
• Describe the underlying pathophysiological and typical clinical features of GHD as they pertain to therapeutic targets.
• Given a patient with GHD, design a pharmacotherapeutic regimen based on his or her clinical presentation.
• Assess and properly manage the significant comorbidities that are associated with GHD and therefore increase mortality in patients with GHD
• Evaluate patient cases during follow-up visits in a manner that optimizes one or more of the following: efficacy, safety, quality of life, or patient education and adherence.
In order to get credit from ScientiaCME, you must first establish a username and password.

Target Audiences:
Healthcare professionals specializing in endocrinology and those who otherwise commonly care for or clinically encounter adult patients with GHD.

ScientiaCME Neuropsychiatry-Neurology contains 4 lectures:
• Parkinson’s disease: Highlights from the American Academy of Neurology 2017 Annual Meeting (AAN 2017)
• Migraine Headaches: Highlights from the American Academy of Neurology 2016 Annual Meeting (AAN 2016)
• Alzheimer Disease (AD) and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care
• Multiple Sclerosis (MS) and Its Complications: Highlights from the AAN 2016 : Take-Aways, Emerging Practice Changes, and Barriers to their Implementation.

In order to get credit from ScientiaCME, you must first establish a username and password.

Target Audience: Neurologists